Molecular targeted therapy for hepatocellular carcinoma

Area of Science:

• Hepatobiliary cancers
• Medical oncology
• Molecular targeted therapy

Background:

• Hepatocellular carcinoma (HCC) frequently presents at advanced stages, limiting treatment options like transplantation or resection.
• Systemic chemotherapy offers minimal efficacy and significant toxicity for HCC, with no proven survival benefit.
• HCC exhibits inherent chemoresistance, partly due to overexpression of multidrug resistance genes, and molecular heterogeneity complicates target identification.

Purpose of the Study:

• To review the challenges in treating advanced Hepatocellular Carcinoma (HCC).
• To discuss the molecular alterations in HCC that present therapeutic challenges.
• To highlight the progress in developing molecularly targeted agents for HCC.

Main Methods:

• Review of current literature on Hepatocellular Carcinoma (HCC) treatment.
• Analysis of molecular mechanisms and therapeutic targets in HCC.
• Evaluation of recent clinical trial data for targeted therapies in HCC.

Main Results:

• Advanced Hepatocellular Carcinoma (HCC) is common, and conventional chemotherapy is largely ineffective.
• Molecular heterogeneity in HCC complicates the identification of specific therapeutic targets.
• Randomized trials demonstrate a survival benefit for HCC patients treated with the targeted oral agent sorafenib.

Conclusions:

• Targeted therapies represent a significant advancement in managing advanced Hepatocellular Carcinoma (HCC).
• Sorafenib offers a survival advantage, indicating the potential of molecularly targeted agents in HCC treatment.
• Further research into HCC's molecular pathways is crucial for developing more effective therapies.